|
Sep 27
|
Longboard Pharmaceuticals begins Phase III Dravet syndrome trial
|
|
Sep 26
|
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
|
|
Aug 28
|
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
|
|
Aug 26
|
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
|
|
Aug 26
|
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
|
|
Aug 4
|
Is Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Trading At A 40% Discount?
|
|
Jul 29
|
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
|
|
Jul 25
|
Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Jul 23
|
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
|
|
May 7
|
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
|
|
May 4
|
Longboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic Developments
|
|
May 2
|
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
|
May 1
|
Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
|
|
Apr 3
|
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
|
|
Mar 27
|
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%
|
|
Mar 14
|
Longboard Pharmaceuticals Inc Reports Full Year 2023 Financial Results
|
|
Mar 12
|
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
|
|
Mar 1
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
|
Jan 2
|
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
|
|
Jan 1
|
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
|